RCLF SEC filings, in plain English
Everything Rosecliff Acquisition Corp I has filed with the SEC that we hold — 40 filings, newest first, 4 with a plain-English summary of what changed and why it matters. Every row links to the primary document on EDGAR, so you can check the source rather than trust us.
The feed
live EDGAR captureNew filings appear here within minutes of hitting EDGAR; summaries follow once the pipeline has read them.
What changed: Exhibit 99.1 to an 8-K of Spectral AI, Inc. (Nasdaq: MDAI): the August 11, 2026 press release reporting Q2 2026 results. Research and development revenue was $3.5 million versus $5.1 million, and $7.5 million versus $11.8 million for the year to date, which the company attributes to reduced reimbursed costs under its BARDA Project BioShield contract following FDA clearance and to cost-share provisions of the follow-on development phase under which the company funds part of its own development costs. Gross margin was 31.6% versus 45.2% in the quarter and 41.8% versus 46.4% year to date. Why it matters: Government-funded development revenue is contracting by design as the BARDA contract moves to a cost-share phase, while commercial sales have not yet begun — the first are targeted for year end 2026. The narrower net loss comes from warrant fair-value movement, not operations.
What changed: The 10-Q filed for the quarter ended June 30, 2026 is that of Spectral AI, Inc. (Nasdaq: MDAI, warrants at $2.75), with 32,184,928 shares outstanding as of August 11, 2026. Research and development revenue fell to $3,524 thousand for the quarter from $5,065 thousand and to $7,515 thousand for the six months from $11,772 thousand, while total operating costs rose to $5,437 thousand from $4,413 thousand, widening the operating loss to $4,324 thousand from $2,123 thousand; the net loss was $4,176 thousand for the quarter and $7,588 thousand for the six months. Why it matters: Revenue halved over six months while debt rose $6.5 million, and warrant liabilities of $11.8 million alone exceed half of total assets. Total liabilities are $31.5 million against $19.4 million of assets, and $3.9 million of notes come due within the year against $14.0 million of cash.
What changed: Spectral AI, Inc., the Rosecliff Acquisition Corp I successor, filed the July 7, 2026 offer letter appointing Darcy L. Bajko as Chief Commercial Officer with an anticipated start date of July 31, 2026, subject to a background check, reporting to Chief Executive Officer Vince Capone. The annual salary is $315,000, with eligibility for a discretionary annual bonus of up to 30% of salary based on perceived performance and contribution to revenue and profitability, and 401(k) participation after three months with a dollar-for-dollar match up to 6% of base salary. Why it matters: Routine executive hiring with no trust, redemption right or deadline in play. The signal is commercial rather than governance: a company appointing its first named Chief Commercial Officer at a $315,000 salary with a bonus tied explicitly to revenue and profitability is staffing to convert a development-stage product into sales. The cash cost is small and no equity grant appears in the captured text, so there is no measurable dilution for former RCLF holders from this appointment.
What changed: Spectral AI, Inc., the successor to Rosecliff Acquisition Corp I, called its 2026 annual meeting for Friday, May 29, 2026 at 9:30 a.m. Central Daylight Time, held both at its Dallas headquarters at 2515 McKinney Avenue, Suite 1000 and virtually, record date April 1, 2026. Beyond director elections and ratification of Forvis Mazars, LLP for fiscal 2026, holders are asked to authorize, for purposes of Nasdaq Marketplace Rule 5635(b), the reservation and issuance of common stock for sale to Hudson Bay Master Fund at a price determined under a Purchase Agreement. Why it matters: Nasdaq Rule 5635(b) is the change-of-control rule, not the 20% rule - a vote under it means the contemplated issuance to Hudson Bay could hand a single investor effective control of the company. Combined with a purchase price set by formula under the Purchase Agreement rather than fixed, holders are being asked to approve open-ended dilution to one counterparty, weeks after a CEO change in February 2026.
- What changed vs 2025-03-31mandate language changed
mandate language1 moved
Read from stored SEC filing text by a regex — no model is involved — and each side links to the filing it came from. “Not previously extracted” is a statement about our record, not about the company: the clause may be present in wording we do not match.
In plain English
Redemption deadlinethe last day to hand shares back for cash
Set by the filing that calls the meeting. Tender after it and the company is under no obligation to pay you the trust value.
Cash in trust / trust per sharethe cash the company is holding for each public share
Filed quarterly in the 10-Q's XBRL. It earns interest between filings, so the figure on a given day is slightly higher than the last filed one — where we show that we label it an estimate.
Accession numberthe SEC's unique id for one filing
Every figure on this page carries the accession of the filing that states it, so you can open the primary document rather than trust us.